| Sign In to gain access to subscriptions and/or personal tools. |
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion
Oncology Department, Queen's Hospital, Rom Valley Way, Romford, Essex, RM7 0AG, UK
* To whom correspondence should be addressed.
Introduction. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) chemotherapy and is licenced for the treatment of breast and gastrointestinal cancers. Multifocal inflammatory leukoencephalopathy has been associated with intravenous 5-FU, but only a few cases of capecitabine-induced encephalopathy have been reported. Setting. We describe here a case of encephalopathy following administration of Epirubicin/Cisplatin/Capecitabine chemotherapy, review those cases previously described and suggest recommendations for management. Results. Symptoms of neurotoxicity from 5-FU and capecitabine usually include confusion, ataxia, nystagmus, dysarthria, sensory loss, and memory loss. Withdrawal of the drug generally leads to improvement of symptoms and steroids are of only questionable benefit. Conclusion. Patients on fluouropyrimidine drugs with new neurological symptoms should be investigated with brain MRI scan and the drug should be withdrawn until symptoms resolve. Dihydropyrimidine dehydrogenase deficiency should be excluded and ideally an alternative chemotherapy regime sought. We would encourage reporting of such incidences to gain a clearer picture of the incidence and optimal management. Key Words: neurotoxicity, encephalopathy, capecitabine, oesophageal adenocarcinoma, chemotherapy
First published on March 10, 2009 |
||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
